Y Li1, Y-Y Wang, H-R Fei, L Wang, C-L Yuan. 1. Department of Hematology, Qing-dao Central Hospital, Qing-dao, China. lyyycn@yeah.net.
Abstract
OBJECTIVE: This work aims to observe the efficacy and safety of low-dose rituximab in combination with recombinant human thrombopoietin in treating immune thrombocytopenia (ITP). PATIENTS AND METHODS: Fourteen ITP patients were treated four times with 100 mg qw of rituximab in combination with 300 µg/kg/d ih recombinant human thrombopoietin (rhTPO) for 14 d. Platelet count in peripheral blood, serum immunoglobulin, and lymphocyte subgroups by flow cytometry were detected regularly both pre- and post-treatment. RESULTS: Among the 14 patients, seven complete responses, six responses, and one no response were obtained, with an overall response of 93%. CONCLUSIONS: Low-dose rituximab in combination with rhTPO is effective in treating ITP.
OBJECTIVE: This work aims to observe the efficacy and safety of low-dose rituximab in combination with recombinant humanthrombopoietin in treating immune thrombocytopenia (ITP). PATIENTS AND METHODS: Fourteen ITP patients were treated four times with 100 mg qw of rituximab in combination with 300 µg/kg/d ih recombinant humanthrombopoietin (rhTPO) for 14 d. Platelet count in peripheral blood, serum immunoglobulin, and lymphocyte subgroups by flow cytometry were detected regularly both pre- and post-treatment. RESULTS: Among the 14 patients, seven complete responses, six responses, and one no response were obtained, with an overall response of 93%. CONCLUSIONS: Low-dose rituximab in combination with rhTPO is effective in treating ITP.
Authors: Rajan Kapoor; Rajiv Kumar; M Mahapatra; H P Pati; Suman Kumar Pramanik Journal: Indian J Hematol Blood Transfus Date: 2016-12-19 Impact factor: 0.900